Inhaled non-viral delivery systems for RNA therapeutics
Open Access
- 19 March 2025
- journal article
- review article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (5) , 2402-2430
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2023YFC3403100, 2023YFC3403304, 2023YFE0204900, 2023YFC3403303)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z231100007223007)
- National Natural Science Foundation of China (22305140, 82073404, 22175107)
This publication has 172 references indexed in Scilit:
- Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary deliveryDrug Delivery and Translational Research, 2023
- Biomineralized Two‐Enzyme Nanoparticles Regulate Tumor Glycometabolism Inducing Tumor Cell Pyroptosis and Robust Antitumor ImmunotherapyAdvanced Materials, 2022
- Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 InfectionAdvanced Science, 2022
- Nonviral Delivery of CRISPR/Cas Systems in mRNA FormatAdvanced NanoBiomed Research, 2022
- Pseudoscience and fraudulent products for COVID-19 managementEnvironmental Science and Pollution Research, 2022
- T‐cell targeted pulmonary siRNA delivery for the treatment of asthmaWIREs Nanomedicine and Nanobiotechnology, 2020
- Pulmonary delivery of therapeutic siRNAAdvanced Drug Delivery Reviews, 2012
- Inhaled Drug Delivery for Tuberculosis TherapyPharmaceutical Research, 2009
- Role of Particle Size in Phagocytosis of Polymeric MicrospheresPharmaceutical Research, 2008
- Aerosol Delivery of Robust Polyethyleneimine– DNA Complexes for Gene Therapy and Genetic ImmunizationMolecular Therapy, 2000